Citigroup Inc Logic Bio Therapeutics, Inc. Transaction History

Citigroup Inc

  • $153 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
BUY
$0.35 - $0.74 $660 - $1,397
1,888 New
1,888 $1,000

About LogicBio Therapeutics, Inc.

LOGC Quotes by TradingView
  • Ticker LOGC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,962,700
  • Description
  • LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...
More about LOGC
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email